Larimar Pharma (LRMR): Price-to-Revenue Ratio

Larimar Therapeutics (LRMR) is implementing ESG standards to reduce laboratory waste. The development of drugs for Friedreich's ataxia relies on automated substance synthesis. Business stability is ensured by the support of major funds regardless of macroeconomic conditions. The company's revenue valuation on GURU.Markets includes multiplier dynamics, where the value serves as the baseline indicator of market value relative to earnings.

To construct a defensive portfolio, fundamental screening utilizes the P/S multiple, which determines the market value of one dollar of sales by dividing market capitalization by revenue. In the case of Larimar Therapeutics (LRMR), changes in the price-to-sales ratio reflect investor expectations of a future monopoly in the orphan drug market, where the potential for ultra-high pricing combined with low costs justifies the current capital burn.